Bio-Techne’s Advanced Cell Diagnostics (ACD) sets new standard in spatial biology with protease-free RNAscope multiomics

Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow.

Advanced Analytics Can Change the Game for Consumer Healthcare Services

Sean Crandell. SVP of Healthcare Economics at MultiPlan Data has become the lifeblood of healthcare, making it possible to gain granular insights that enable more

January 5, 2024

HIMSS24 Roundup: M&A, Strategic Partnerships, Funding, More

Strategic Partnerships New Consortium Aims to Ensure Responsible Use of AI in Healthcare A new initiative, the Trustworthy & Responsible AI Network (TRAIN), was announced

March 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Bio-Techne’s Advanced Cell Diagnostics (ACD) sets new standard in spatial biology with protease-free RNAscope multiomics

Advanced Analytics Can Change the Game for Consumer Healthcare Services

HIMSS24 Roundup: M&A, Strategic Partnerships, Funding, More

CDCA7 identified as key player in hemimethylation sensing

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe